|
BUSINESS STRATEGY
Scotgen pursued a dual strategy of carrying out contract research for clients while using the profit from these activities for own-product development programmes.
Contract Research Services.
Scotgen successfully developed 25 humanised antibodies between 1987 and 1992, 15 for clients worldwide. These included Biogen, T cell Sciences, Medarex, ICOS, Cytogen, Farmitalia Carlo Erba, Nissin, Vasocor. Many of these products are proceeding to clinical trials.
Own Product Developments.
Anti-infective therapeutic products developed up to 1992 included those for treatment of respiratory syncytial virus (RSV), varicella zoster (chicken pox/shingles), cytomegalovirus and rabies. The RSV product was licensed to Smith Kline Beecham in 1991 but was not pursued after completion of early phase II clinical trials.
Four anti-cancer antibodies were developed in collaboration with Sloan-Kettering Institute for Cancer Research and Ludwig Institute of Cancer Research, New York.
Research programmes
Research to exploit the properties of antibody fragments was initiated in 1989 to develop these for formulations in cancer therapy and for topical delivery as DERMABS. Proprietary technologies to stabilise heavy and light chain associations in these small fragments were under investigation.
|
|
